Chemomab Therapeutics, the pharmaceutical company behind the SPRING trial, announced last week that the authority that oversees medicine development in the USA (the U.S. Food and Drug Administration, or FDA) has granted CM-101 Fast Track designation for the treatment of primary sclerosing cholangitis (PSC).

Fast Track designation is a special status given to some drugs that are addressing the unmet needs for some serious conditions. This means that the necessary regulatory checks for CM-101 could be faster than for those without the status. If the research assessing CM-101 in PSC yields positive results, the Fast Track designation will ultimately speed up the time it takes for the drug to become available as a treatment.

The results of the current Phase 2 SPRING trial are expected in 2024. We are watching closely!